PMID- 20420877
OWN - NLM
STAT- MEDLINE
DCOM- 20101102
LR  - 20221207
IS  - 1878-4216 (Electronic)
IS  - 0278-5846 (Linking)
VI  - 34
IP  - 6
DP  - 2010 Aug 16
TI  - The study of BDNF Val66Met polymorphism in Chinese schizophrenic patients.
PG  - 930-3
LID - 10.1016/j.pnpbp.2010.04.019 [doi]
AB  - Accumulating evidence showed that brain-derived neurotrophic factor (BDNF) may be 
      involved in the pathophysiology of schizophrenia. Recent studies have reported 
      that the Val66Met polymorphism of the BDNF gene may be associated with 
      susceptibility for schizophrenia and age of onset of this disease, with mix 
      results. In the present study, the BDNF Val66Met gene polymorphism was examined 
      in 387 inpatients (259 men and 128 women) meeting the DSM-IV criteria for 
      schizophrenia and unrelated 365 healthy controls (255 men and 110 women). The 
      schizophrenia symptomatology was assessed by the Positive and Negative Syndrome 
      Scale (PANSS). Age of onset was defined as the age at which the psychotic 
      symptoms first appeared. Our results showed that genotype frequency distributions 
      and allelic frequencies did not differ between patients and controls. No 
      interaction was found between sex and genotypes. Analysis of covariance (ANCOVA) 
      showed a significance of the BDNF Val66Met genotypes on the age of onset (F=3.76, 
      p<0.02), after adjusting sex, age and duration of illness. Furthermore, ANCOVA 
      showed that the significance of the BDNFVal66Met genotypes on age of onset was 
      increased comparing the Val66Met heterozygotes with the combination of Val66Val 
      and Met66Met homozygotes (F=5.85, p<0.01). Our results suggest that the BDNF 
      Val66Met polymorphism may not contribute directly to the susceptibility to 
      schizophrenia, but to the onset of the disease. Furthermore, our results show the 
      heterozygous effect of the BDNF Val66Met gene on the clinical variability of 
      schizophrenia phenotype.
CI  - Copyright (c) 2010 Elsevier Inc. All rights reserved.
FAU - Zhou, Dong Hao
AU  - Zhou DH
AD  - Department of Internal Medicine, Hebei Medical University, Shijiazhuang 050017, 
      China.
FAU - Yan, Quan Zhi
AU  - Yan QZ
FAU - Yan, Xiao Mei
AU  - Yan XM
FAU - Li, Cun Bao
AU  - Li CB
FAU - Fang, Hui
AU  - Fang H
FAU - Zheng, You Lan
AU  - Zheng YL
FAU - Zhang, Chong Xi
AU  - Zhang CX
FAU - Yao, Hui Jun
AU  - Yao HJ
FAU - Chen, Da Chun
AU  - Chen DC
FAU - Xiu, Mei Hong
AU  - Xiu MH
FAU - Kosten, Thomas R
AU  - Kosten TR
FAU - Zhang, Xiang Yang
AU  - Zhang XY
LA  - eng
GR  - K05-DA0454/DA/NIDA NIH HHS/United States
GR  - P50-DA18827/DA/NIDA NIH HHS/United States
GR  - U01-MH79639/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20100424
PL  - England
TA  - Prog Neuropsychopharmacol Biol Psychiatry
JT  - Progress in neuro-psychopharmacology & biological psychiatry
JID - 8211617
RN  - 0 (Brain-Derived Neurotrophic Factor)
SB  - IM
MH  - Adult
MH  - Age of Onset
MH  - Analysis of Variance
MH  - Asian People/genetics
MH  - Brain-Derived Neurotrophic Factor/*genetics
MH  - Female
MH  - Gene Frequency
MH  - Genetic Predisposition to Disease
MH  - Genotype
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Polymerase Chain Reaction
MH  - Polymorphism, Single Nucleotide
MH  - Schizophrenia/*genetics
EDAT- 2010/04/28 06:00
MHDA- 2010/11/03 06:00
CRDT- 2010/04/28 06:00
PHST- 2010/01/06 00:00 [received]
PHST- 2010/04/14 00:00 [revised]
PHST- 2010/04/20 00:00 [accepted]
PHST- 2010/04/28 06:00 [entrez]
PHST- 2010/04/28 06:00 [pubmed]
PHST- 2010/11/03 06:00 [medline]
AID - S0278-5846(10)00148-X [pii]
AID - 10.1016/j.pnpbp.2010.04.019 [doi]
PST - ppublish
SO  - Prog Neuropsychopharmacol Biol Psychiatry. 2010 Aug 16;34(6):930-3. doi: 
      10.1016/j.pnpbp.2010.04.019. Epub 2010 Apr 24.